Overview A Phase 1, Open-Label, 10 Day Safety Study Status: Completed Trial end date: 2012-08-24 Target enrollment: Participant gender: Summary This is a Phase 1 open-label study in healthy volunteers who will receive oral 200 mg TR 701 FA once daily for 10 days and will include ophthalmologic and neurologic assessments. Phase: Phase 1 Details Lead Sponsor: Trius Therapeutics LLCTreatments: TedizolidTedizolid phosphateTorezolid phosphate